Last reviewed · How we verify
MSP3 candidate vaccine
At a glance
| Generic name | MSP3 candidate vaccine |
|---|---|
| Sponsor | African Malaria Network Trust |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- MSP3-CRM-Vac4All/ Alhydrogel® Vaccine (PHASE1, PHASE2)
- Proof-of-Concept Study of MSP3-LSP Vaccine to Protect Against Malaria in Africa (PHASE2)
- A Phase Ib Trial of MSP 3 LSP in 1-2 Year Old Children in Burkina Faso (PHASE1)
- Immunogenicity, Efficacy and Safety Study of an MSP3-LSP (Long Synthetic Peptide) Malaria Vaccine (PHASE2)
- Phase Ib Trial of MSP3 LSP in Children in Tanzania (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MSP3 candidate vaccine CI brief — competitive landscape report
- MSP3 candidate vaccine updates RSS · CI watch RSS
- African Malaria Network Trust portfolio CI